E Fund Management Co. Ltd. Has $477,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

E Fund Management Co. Ltd. grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 8.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 21,217 shares of the biotechnology company’s stock after acquiring an additional 1,705 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Exelixis were worth $477,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. LSV Asset Management lifted its position in Exelixis by 1,651.4% during the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock worth $65,844,000 after purchasing an additional 2,616,278 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of Exelixis by 948.3% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after acquiring an additional 2,220,150 shares during the period. True Wealth Design LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $828,000. Intech Investment Management LLC increased its stake in Exelixis by 155.8% in the first quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock valued at $2,374,000 after acquiring an additional 60,925 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Exelixis during the first quarter valued at approximately $1,281,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Tuesday, July 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research report on Wednesday, August 7th. JMP Securities boosted their target price on Exelixis from $27.00 to $29.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Finally, Truist Financial reiterated a “buy” rating and set a $33.00 price objective (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 95,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Jeffrey Hessekiel sold 20,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.79, for a total transaction of $515,800.00. Following the sale, the executive vice president now owns 630,325 shares in the company, valued at approximately $16,256,081.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at $13,024,750. The disclosure for this sale can be found here. Insiders have sold a total of 302,858 shares of company stock valued at $7,980,629 over the last ninety days. 2.85% of the stock is owned by company insiders.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $26.82 on Thursday. Exelixis, Inc. has a 52 week low of $18.64 and a 52 week high of $27.83. The firm has a market cap of $8.13 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 0.58 and a beta of 0.54. The firm’s fifty day moving average is $24.94 and its 200-day moving average is $23.26.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The firm had revenue of $637.18 million for the quarter, compared to the consensus estimate of $468.21 million. Sell-side analysts forecast that Exelixis, Inc. will post 1.54 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.